Please use this identifier to cite or link to this item:
Title: Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults
Authors: Tim R. Cressey
Rohan Hazra
Andrew Wiznia
Marc Foca
Patrick Jean-Philippe
Bobbie Graham
Jennifer R. King
Paula Britto
Vincent J. Carey
Edward P. Acosta
Ram Yogev
Keywords: Medicine
Issue Date: 28-Nov-2016
Abstract: © 2016 Wolters Kluwer Health, Inc. All rights reserved. HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.
ISSN: 15320987
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.